Age-related physiological changes, particularly immune system decline, may contribute to greater vulnerability to infectious diseases in older individuals.

What do we know so far about older adults and COVID-19 vaccines? How long does the effect of the vaccine last and how successful have countries been in vaccinating older adults? WHO’s Dr Katherine O’Brien explains in Science in 5

Respiratory syncytial virus (RSV) is a leading cause of lower respiratory infections in infants and the immunocompromised, yet no efficient therapeutic exists. We have identified the AVG class of allosteric inhibitors of RSV RNA synthesis.

Although human respiratory syncytial virus (RSV) is an important cause of illness and death in older adults, no RSV vaccine has been licensed.

Who is at an increased risk of adverse effects from an RSV infection? What is the burden of disease and what should be done to alleviate the risk and increase awareness?

An infectious etiology of Alzheimer’s disease has been postulated for decades. It remains unknown whether SARS-CoV-2 viral infection is associated with increased risk for Alzheimer’s disease.

Respiratory syncytial virus is the second most common cause of infant mortality and a major cause of morbidity and mortality in older adults (aged >60 years).

Respiratory syncytial virus is the second most common cause of infant mortality and a major cause of morbidity and mortality in older adults (aged >60 years).

In this human infection challenge pilot study, adults aged 18–55 years and 60–75 years were assessed for enrolment using protocol-defined inclusion and exclusion criteria.

High-dose influenza vaccines provide better protection against influenza infection than standard-dose in persons aged 65 years and above.

Fourth webinar in the series: Preparing for COVID-19, RSV disease and Inlfuenza concomitant outbreaks, chaired by Ab Osterhaus and Peter ...